Copyright
©The Author(s) 2024.
World J Diabetes. Apr 15, 2024; 15(4): 769-782
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.769
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.769
Figure 1 Icariin promoted bone marrow mesenchymal stem cell proliferation and osteogenic differentiation.
A: Bone marrow mesenchymal stem cell (BMSC) surface markers were detected by flow cytometry; B: Icariin (ICA) chemical structure; C: The effect of ICA on BMSC proliferation was measured by the cell counting kit-8 assay; D: Representative images of the colony-forming unit (CFU) assay to determine the effect of ICA on BMSC proliferation; E: Quantification of the CFU assay; F: Representative images of alkaline phosphatase (ALP) staining (scale bar: 250 μm); G: ALP activity detection; H: Representative images of alizarin red S (ARS) staining (scale bar: 250 μm); I: Semi-quantitative result of ARS staining. Data are mean ± SEM (n = 5). aP < 0.05 and bP < 0.01 vs control group; cP < 0.05 and dP < 0.01 vs 1 μM ICA group. ICA: Icariin.
- Citation: Zheng S, Hu GY, Li JH, Zheng J, Li YK. Icariin accelerates bone regeneration by inducing osteogenesis-angiogenesis coupling in rats with type 1 diabetes mellitus. World J Diabetes 2024; 15(4): 769-782
- URL: https://www.wjgnet.com/1948-9358/full/v15/i4/769.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i4.769